Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Clementia Pharmaceuticals Inc. (NASDAQ: CMTA).

Full DD Report for CMTA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CMTA)

Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates
On Track to Report Data from Part B of its Phase 2 Study of Palovarotene for Fibrodysplasia Ossificans Progressiva This Quarter Enrollment in Phase 3 MOVE Trial On Track, Phase 2 MO-Ped Trial Underway MONTREAL, May 09, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NA...
Source: GlobeNewswire
Date: May, 09 2018 06:30
Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas
Stock Monitor: Ovid Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Clementia Pharma Inc. (NASDAQ: CMTA ). If you want access to this report all you need to do is sign up now by clicking t...
Source: ACCESSWIRE IA
Date: April, 24 2018 07:00
Your Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration
A nalysis focus: Abeona Therapeutics Today we will discuss Abeona Therapeutics (NASDAQ: ABEO ), which is up more than 5% in early trading after announcing that the European Medicines Agency (EMA) has granted its gene therapy AB-202 an Orphan Drug designation for the treatment of ne...
Source: SeekingAlpha
Date: April, 23 2018 08:00
Midday Gainers / Losers (04/20/2018)
Gainers:   DRNA +38% . LLNW +22% . ERIC +17% . NAP +16% . FFKT +16% . CALI +12% . CIDM +12% . MYO +10% . OFG +10% . SSW +9% . More news on: Dicerna Pharmaceuticals, Inc., Limelight Networks, Inc., LM Ericsson Telephone Company, Stocks on the move, , ...
Source: SeekingAlpha
Date: April, 20 2018 12:55
Clementia launches mid-stage study of palovarotene in pediatric bone tumors
Clementia Pharmaceuticals (NASDAQ: CMTA ) commences a Phase 2 clinical trial, MO-Ped, assessing lead candidate palovarotene in pediatric patients with multiple osteochondromas , the most common benign tumors of the bones. They appear as growths on the surface of a bone near the growth pla...
Source: SeekingAlpha
Date: April, 20 2018 07:28
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
MONTREAL, April 20, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the start of the MO-Ped Trial, its Phase 2 study evaluating the saf...
Source: GlobeNewswire
Date: April, 20 2018 06:30
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Korea Electric Power Corporation (...
Source: GlobeNewswire
Date: April, 13 2018 08:20
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) , MyoKardia, Inc. (N...
Source: GlobeNewswire
Date: March, 16 2018 08:15
Clementia to Present at the Cowen and Company 38th Annual Health Care Conference
MONTREAL, March 06, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive ...
Source: GlobeNewswire
Date: March, 06 2018 06:30
Clementia Reports 2017 Operating Results and Business Highlights
Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter MONTREAL, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Clementia P...
Source: GlobeNewswire
Date: February, 28 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1717.5818.2518.787417.5812,505

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1311,17214,98374.5645Short
2018-08-109,90918,12954.6583Short
2018-08-0910,81320,98451.5297Short
2018-08-0817,53422,74677.0861Short
2018-08-0711,23320,63754.4314Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CMTA.


About Clementia Pharmaceuticals Inc. (NASDAQ: CMTA)

Logo for Clementia Pharmaceuticals Inc. (NASDAQ: CMTA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CMTA)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 06 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: February, 28 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 28 2018

       

       


      Daily Technical Chart for (NASDAQ: CMTA)

      Daily Technical Chart for (NASDAQ: CMTA)


      Stay tuned for daily updates and more on (NASDAQ: CMTA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CMTA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CMTA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CMTA and does not buy, sell, or trade any shares of CMTA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/